Breaking News Instant updates and real-time market news.

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:53
10/21/18
10/21
13:53
10/21/18
13:53

Loxo announces larotrectinib clinical update in patients with TRK fusion cancers

Loxo Oncology (LOXO) announced updated clinical data for larotrectinib, an investigational oral, selective, and CNS-active TRK inhibitor, in adult and pediatric patients with TRK fusion cancers. The update included approximately one year of additional follow-up for the 55 patients described in the larotrectinib New England Journal of Medicine publication from February 2018. In addition, the update included data for an additional 67 patients who were subsequently enrolled across the larotrectinib development program. As of a data cut-off date of July 30, 2018, median duration of response had not been reached in either dataset. Loxo Oncology and Bayer (BAYRY) are engaged in a collaboration for the development and commercialization of larotrectinib. The U.S. Food and Drug Administration has accepted the New Drug Application submitted by Loxo Oncology, and granted Priority Review for larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring a neurotrophic tyrosine receptor kinase gene fusion. The FDA has set a target action date of November 26, 2018, under the Prescription Drug User Fee Act. Bayer has submitted a Marketing Authorization Application in the EU and additional filings in other markets are underway. Larotrectinib was well tolerated, with the majority of adverse events recorded as grade 1 or 2. No treatment-related grade 3 or 4 adverse events occurred in more than 5% of patients. Eleven patients required larotrectinib dose reductions. In all cases, patients whose doses were reduced maintained their best response at the lower dose. One patient discontinued larotrectinib due to an adverse event.

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

LOXO Loxo Oncology
$160.01

-7.58 (-4.52%)

10/08/18
10/08/18
UPGRADE
Target $190

Outperform
Loxo Oncology upgraded to Outperform on LOXO-292 update at IFS Securities
As previously reported, IFS Securities analyst David Bouchey upgraded Loxo Oncology to Outperform from Market Perform, with $190 price target, after the company reported updated results from its Phase I/II trial for LOXO-292. The analyst believes the response rates for LOXO-292 continue to look "very strong," the safety data is "excellent" and early results show that these responses appear durable. So far, the drug has outperformed expectations, he adds.
10/08/18
IFSG
10/08/18
UPGRADE
IFSG
Outperform
Loxo Oncology upgraded to Outperform from Market Perform at IFS Securities
10/07/18
PIPR
10/07/18
NO CHANGE
Target $200
PIPR
Overweight
Loxo Oncology's 292 remains on top after RET data updates, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren reiterates an Overweight rating and $200 price target for Loxo Oncology (LOXO) after the company provided an update of the thyroid patients in the Phase I/II study of LOXO-292. The analyst highlights that in the largest patient population the response rate increased from 45% to 59% with three additional patients responding between 9 and 12 months. Blueprint Medicines' (BPMC) competing BLU-667 reported a 49% ORR in a similar patient population and recall that adverse events of hypertension are still a concern, he notes. Van Buren believes that the 667's safety profile could continue to look worse as it continues to administer the drug to patients at higher doses and that treatment discontinuations could increase. Overall, the analyst believes Loxo's 292 appears to be the superior RET inhibitor in development, both in terms of efficacy and safety and could easily become a $1B+ drug.
09/26/18
STFL
09/26/18
NO CHANGE
Target $217
STFL
Buy
Loxo data not 'transformational,' but keeps inspiring confidence, says Stifel
Stifel analyst Stephen Willey said the incremental follow-up data from Loxo Oncology's (LOXO) LIBRETTO-001 trial isn't "transformational," but it does confirm his confidence in the establishment of a high competitive hurdle for LOXO-292, which he sees being a "best-in-class" and first-to-market asset in a $1B+ market. He remains confident LOXO-292 is the superior asset, but acknowledges the anticipation of Blueprint Medicines' (BPMC) updated BLU-667 data at some point in late-FY18 to early-FY19 could serve as a bit of headwind on Loxo shares nearer to that data release. Willey keeps a Buy rating and $217 price target on Loxo shares.
BAYRY Bayer
$0.00

(0.00%)

09/20/18
SBSH
09/20/18
UPGRADE
SBSH
Buy
Bayer upgraded to Buy from Neutral at Citi
Citi analyst Peter Verdult upgraded Bayer to Buy saying the current risk/reward is "difficult to ignore" with investor sentiment at "rock bottom." The analyst believes the negative earnings revisions have likely bottomed out.
09/18/18
09/18/18
UPGRADE

Bayer upgraded to Buy from Hold at M.M. Warburg
M.M. Warburg analyst Ulrich Huwald upgraded Bayer to Buy and raised his price target for the shares to EUR 88.50 from EUR 85.
09/11/18
EXAN
09/11/18
DOWNGRADE
EXAN
Neutral
Bayer downgraded to Neutral from Outperform at Exane BNP Paribas
08/27/18
08/27/18
UPGRADE
Target $34

Neutral
Portola Pharmaceuticals upgraded to Neutral as MARINER sinks at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Portola Pharmaceuticals (PTLA) to Neutral from Underperform after Johnson & Johnson (JNJ)/Bayer (BAYRY) presented disappointing data for Xarelto in the acute medically ill population at ESC. The analyst notes that the data avoids a worst case scenario for Portola's Bevyxxa by essentially removing a potentially strong competitor, but does put the pressure on Portola to successfully change medical practice on its own, without help from a larger player such as Johnson & Johnson. Divan also raised his price target on Portola's shares to $34 from $28.

TODAY'S FREE FLY STORIES

HYMTF

Hyundai Motor

$0.00

(0.00%)

21:09
03/21/19
03/21
21:09
03/21/19
21:09
Periodicals
Breaking Periodicals news story on Hyundai Motor »

Elliott Management loses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMTS

Sierra Metals

$1.64

0.05 (3.14%)

21:01
03/21/19
03/21
21:01
03/21/19
21:01
Hot Stocks
Sierra Metals announces 66% of Yauricocha Mine workers waged illegal strike »

Sierra Metals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

LGF.B

Lionsgate

$15.17

0.4 (2.71%)

, NFLX

Netflix

$378.09

2.94 (0.78%)

20:32
03/21/19
03/21
20:32
03/21/19
20:32
Recommendations
Lionsgate, Netflix, Apple, Spotify, Roku analyst commentary at SunTrust »

Apple event may be…

LGF.B

Lionsgate

$15.17

0.4 (2.71%)

NFLX

Netflix

$378.09

2.94 (0.78%)

AAPL

Apple

$195.07

6.93 (3.68%)

SPOT

Spotify

$144.04

-0.01 (-0.01%)

ROKU

Roku

$66.82

1.86 (2.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

TSLA

Tesla

$274.10

0.6 (0.22%)

20:13
03/21/19
03/21
20:13
03/21/19
20:13
Hot Stocks
End of Tesla's referral program reduced costs, allowed to pass on savings »

In its blog, Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSBC

HSBC

$41.07

-0.16 (-0.39%)

, BLK

BlackRock

$430.32

0.35 (0.08%)

19:44
03/21/19
03/21
19:44
03/21/19
19:44
Periodicals
Breaking Periodicals news story on HSBC, BlackRock »

HSBC reaches deal to use…

HSBC

HSBC

$41.07

-0.16 (-0.39%)

BLK

BlackRock

$430.32

0.35 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

UBER

Uber

$0.00

(0.00%)

, ICE

IntercontinentalExchange

$73.36

0.15 (0.20%)

19:21
03/21/19
03/21
19:21
03/21/19
19:21
Periodicals
Uber selects NYSE for 2019 IPO, Bloomberg reports »

Uber (UBER) has picked…

UBER

Uber

$0.00

(0.00%)

ICE

IntercontinentalExchange

$73.36

0.15 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 17

    May

  • 28

    May

PIN

Pinterest

$25.63

-0.07 (-0.27%)

19:18
03/21/19
03/21
19:18
03/21/19
19:18
Periodicals
Pinterest moves up IPO timing, seeks to list shares on NYSE in April, WSJ says »

Pinterest has moved up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAP

Molson Coors

$60.80

1.04 (1.74%)

, BUD

AB InBev

$83.94

0.52 (0.62%)

18:57
03/21/19
03/21
18:57
03/21/19
18:57
Periodicals
MillerCoors sues AB InBev over corn syrup claims, WSJ reports »

MillerCoors, a subsidiary…

TAP

Molson Coors

$60.80

1.04 (1.74%)

BUD

AB InBev

$83.94

0.52 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

OSS

One Stop Systems

$2.52

(0.00%)

, AMRN

Amarin

$18.77

-0.24 (-1.26%)

18:40
03/21/19
03/21
18:40
03/21/19
18:40
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: One…

OSS

One Stop Systems

$2.52

(0.00%)

AMRN

Amarin

$18.77

-0.24 (-1.26%)

GME

GameStop

$10.54

0.06 (0.57%)

DLNG

Dynagas LNG

$2.61

0.025 (0.97%)

ZUO

Zuora

$24.34

0.62 (2.61%)

CAL

Caleres

$25.75

-0.08 (-0.31%)

OPNT

Opiant Pharmaceuticals

$14.00

0.5 (3.70%)

NKE

Nike

$88.05

1.3597 (1.57%)

CTAS

Cintas

$208.00

2.78 (1.35%)

CNAT

Conatus

$2.91

0.02 (0.69%)

GG

Goldcorp

$11.17

0.13 (1.18%)

NEM

Newmont Mining

$34.32

0.44 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 25

    Mar

  • 02

    Apr

  • 04

    Apr

  • 04

    Apr

  • 11

    Apr

  • 16

    Apr

  • 23

    Apr

UBER

Uber

$0.00

(0.00%)

, ICE

IntercontinentalExchange

$73.36

0.15 (0.20%)

18:40
03/21/19
03/21
18:40
03/21/19
18:40
Periodicals
Uber selects NYSE for 2019 IPO, Bloomberg reports »

Uber (UBER) has picked…

UBER

Uber

$0.00

(0.00%)

ICE

IntercontinentalExchange

$73.36

0.15 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 17

    May

  • 28

    May

CVS

CVS Health

$57.40

1.23 (2.19%)

18:34
03/21/19
03/21
18:34
03/21/19
18:34
Hot Stocks
CVS Health CEO: Off to great start with Aetna integration »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$284.63

3.19 (1.13%)

18:30
03/21/19
03/21
18:30
03/21/19
18:30
Periodicals
EU to offer U.K. Brexit negotiating period extension, Reuters says »

The EU plans to grant the…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$284.63

3.19 (1.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOK

Nokia

$6.26

-0.03 (-0.48%)

18:20
03/21/19
03/21
18:20
03/21/19
18:20
Periodicals
Nokia not planning to take on new business in Iran in 2019, Reuters says »

Nokia said it does not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

DNR

Denbury Resources

$1.95

0.06 (3.17%)

, PVAC

Penn Virginia

$54.29

1.74 (3.31%)

18:17
03/21/19
03/21
18:17
03/21/19
18:17
Hot Stocks
Denbury Resources: Penn Virginia deal was unlikely to receive majority approval »

Chris Kendall,…

DNR

Denbury Resources

$1.95

0.06 (3.17%)

PVAC

Penn Virginia

$54.29

1.74 (3.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

IMMP

Immutep

$2.40

-0.095 (-3.82%)

18:11
03/21/19
03/21
18:11
03/21/19
18:11
Hot Stocks
Immutep announces U.S. patent for Eftilagimod Alpha in cancer »

Immutep Limited is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PVAC

Penn Virginia

$54.29

1.74 (3.31%)

, DNR

Denbury Resources

$1.95

0.06 (3.17%)

18:08
03/21/19
03/21
18:08
03/21/19
18:08
Hot Stocks
Penn Virginia, Denbury Resources mutually agree to terminate merger pact »

Penn Virginia (PVAC)…

PVAC

Penn Virginia

$54.29

1.74 (3.31%)

DNR

Denbury Resources

$1.95

0.06 (3.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

LLL

L3 Technologies

$208.75

1.535 (0.74%)

17:44
03/21/19
03/21
17:44
03/21/19
17:44
Hot Stocks
L3 Technologies awarded $131.78M Air Force contract »

L3 Technologies has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

  • 01

    May

GM

General Motors

$37.35

0.35 (0.95%)

17:42
03/21/19
03/21
17:42
03/21/19
17:42
Periodicals
GM to invest $300M in Orion EV/AV factory, Reuters reports »

General Motors intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 30

    Apr

GD

General Dynamics

$169.81

1.21 (0.72%)

17:42
03/21/19
03/21
17:42
03/21/19
17:42
Hot Stocks
General Dynamics awarded $465.15M Navy contract for CVN shipyard availabilities »

General Dynamics has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

NKE

Nike

$88.05

1.3597 (1.57%)

17:41
03/21/19
03/21
17:41
03/21/19
17:41
Earnings
Breaking Earnings news story on Nike »

Nike sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 04

    Apr

  • 04

    Apr

NKE

Nike

$88.05

1.3597 (1.57%)

17:39
03/21/19
03/21
17:39
03/21/19
17:39
Earnings
Nike sees Q4 revenue growth in high single-digit range, consensus $10.38B »

Sees Q4 gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 04

    Apr

  • 04

    Apr

NKE

Nike

$88.05

1.3597 (1.57%)

17:36
03/21/19
03/21
17:36
03/21/19
17:36
Hot Stocks
Nike says it is not taking China momentum for granted »

Says leveraging the power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 04

    Apr

  • 04

    Apr

LOV

Spark Networks

$11.29

(0.00%)

17:34
03/21/19
03/21
17:34
03/21/19
17:34
Hot Stocks
Spark Networks to acquire Zoosk, sees adjusted EBITDA to exceed $50M in 2020 »

Spark Networks announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACA

Arcosa

$29.74

-0.16 (-0.54%)

17:29
03/21/19
03/21
17:29
03/21/19
17:29
Initiation
Arcosa initiated at DA Davidson »

Arcosa initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$138.09

0.86 (0.63%)

17:24
03/21/19
03/21
17:24
03/21/19
17:24
Hot Stocks
Johnson & Johnson sees Q1 charge of about $700M related to AL-8176 »

On March 21, Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

  • 25

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.